M&A Review Financial Advisor League Tables - Academic

Comment

Aerami’s upcoming merger with FoxWayne will bolster the company’s PAH portfolio

Proceeds from Aerami’s merger with FoxWayne will help advance the development of the company’s PAH therapy, AER-901 (imatinib).

GlobalData Healthcare